GSK market cap is £71.2 b, and annual revenue was £33.75 b in FY 2019

GSK Gross profit (Q3, 2020)5.8 B

GSK Gross profit margin (Q3, 2020), %66.6%

GSK Net income (Q3, 2020)1.4 B

GSK EBIT (Q3, 2020)1.9 B

GSK Cash, 30-Sept-20204.3 B

GSK EV95.2 B

GSK revenue was £33.75 b in FY, 2019 which is a 9.5% year over year increase from the previous period.

GSK revenue breakdown by business segment: 26.7% from Consumer Healthcare, 21.2% from Vaccines and 52.1% from Global Pharmaceuticals

GSK revenue breakdown by geographic segment: 23.9% from Europe, 34.9% from International and 41.2% from US

GBP | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|

## Revenue | 27.9b | 30.2b | 30.8b | 33.8b |

| 17% | 8% | 2% | 10% |

## Cost of goods sold | 9.3b | 10.3b | 10.2b | 11.9b |

## Gross profit | 18.6b | 19.8b | 20.6b | 21.9b |

| 67% | 66% | 67% | 65% |

## R&D expense | 3.6b | 4.5b | 3.9b | 4.6b |

## General and administrative expense | 9.4b | 9.7b | 9.9b | 11.4b |

## Operating expense total | 16.0b | 15.8b | 15.1b | 16.0b |

## EBIT | 2.6b | 4.1b | 5.5b | 7.0b |

| 9% | 14% | 18% | 21% |

## Interest expense | 701.0m | 720.0m | 717.0m | 879.0m |

## Interest income | 70.0m | 63.0m | 74.0m | 79.0m |

## Pre tax profit | 1.9b | 3.5b | 4.8b | 6.2b |

## Income tax expense | 877.0m | 1.4b | 754.0m | 953.0m |

## Net Income | 1.1b | 2.2b | 4.0b | 5.3b |

## EPS | 0.2 | 0.3 | 0.7 | 0.9 |

GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 7.4b | 7.3b | 7.8b | 7.2b | 7.3b | 8.1b | 7.7b | 7.8b | 9.4b | 9.1b | 7.6b | 8.6b |

## Cost of goods sold | 2.5b | 2.6b | 2.7b | 2.4b | 2.3b | 2.6b | 2.7b | 2.6b | 3.2b | 3.2b | 2.4b | 2.9b |

## Gross profit | 4.9b | 4.7b | 5.2b | 4.8b | 5.0b | 5.5b | 4.9b | 5.2b | 6.1b | 5.9b | 5.2b | 5.8b |

| 66% | 64% | 66% | 67% | 68% | 67% | 64% | 66% | 65% | 65% | 68% | 67% |

## R&D expense | 960.0m | 1.3b | 1.0b | 904.0m | 925.0m | 988.0m | 1.0b | 1.1b | 1.2b | 1.2b | 1.3b | 1.1b |

## General and administrative expense | 2.5b | 2.4b | 2.3b | 2.3b | 2.5b | 2.5b | 2.5b | 2.6b | 2.9b | 2.9b | 2.7b | 2.7b |

## Operating expense total | 3.2b | 4.7b | 3.3b | 3.6b | 4.3b | 3.6b | 3.6b | 3.8b | 4.1b | 4.1b | 4.0b | 4.0b |

## EBIT | 1.7b | (20.0m) | 1.9b | 1.2b | 779.0m | 1.9b | 1.4b | 1.5b | 2.1b | 2.0b | 2.9b | 1.9b |

| 23% | 0% | 24% | 17% | 11% | 24% | 19% | 19% | 23% | 22% | 37% | 21% |

## Pre tax profit | 1.6b | (178.0m) | 1.7b | 1.1b | 614.0m | 1.7b | 1.3b | 1.3b | 2.0b | 1.8b | 2.6b | 1.7b |

## Income tax expense | 327.0m | (92.0m) | 316.0m | 348.0m | 139.0m | 193.0m | 310.0m | 214.0m | 235.0m | 156.0m | 201.0m | 241.0m |

## Net Income | 1.2b | (86.0m) | 1.4b | 759.0m | 475.0m | 1.5b | 985.0m | 1.1b | 1.7b | 1.7b | 2.4b | 1.4b |

## EPS | 0.2 | 0.0 | 0.2 | 0.1 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.3 | 0.5 | 0.2 |

GBP | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|

## Cash | 4.9b | 3.8b | 3.9b | 4.7b |

## Accounts Receivable | 4.6b | 4.7b | 5.2b | 5.5b |

## Inventories | 5.1b | 5.6b | 5.5b | 5.9b |

## Current Assets | 16.7b | 15.9b | 16.9b | 19.5b |

## PP&E | 10.8b | 10.9b | 11.1b | 10.3b |

## Goodwill | 6.0b | 5.7b | 5.8b | 10.6b |

## Total Assets | 59.1b | 56.4b | 58.1b | 79.7b |

## Accounts Payable | 3.6b | 3.5b | 3.6b | 4.1b |

## Short-term debt | 4.1b | 2.8b | 5.8b | 6.9b |

## Current Liabilities | 19.0b | 26.6b | 22.5b | 24.1b |

## Long-term debt | 14.7b | 14.3b | 20.3b | 23.6b |

## Non-Current Liabilities | 35.1b | 26.3b | 31.9b | 37.3b |

## Total Debt | 18.8b | 17.1b | 26.1b | 30.5b |

## Total Liabilities | 54.1b | 52.9b | 54.4b | 61.3b |

## Common Stock | 1.3b | 1.3b | 1.3b | 1.3b |

## Additional Paid-in Capital | 3.0b | 3.0b | 3.1b | 3.2b |

## Retained Earnings | (5.4b) | (6.5b) | (2.1b) | 4.5b |

## Total Equity | 5.0b | 3.5b | 4.4b | 18.4b |

## Debt to Equity Ratio | 3.8 x | 4.9 x | 6 x | 1.7 x |

## Debt to Assets Ratio | 0.3 x | 0.3 x | 0.4 x | 0.4 x |

## Financial Leverage | 11.9 x | 16.2 x | 13.3 x | 4.3 x |

GBP | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|

## Net Income | 1.1b | 2.2b | 4.0b | 5.3b |

## Depreciation and Amortization | 1.6b | 1.9b | 1.9b | 2.3b |

## Accounts Receivable | (188.0m) | (287.0m) | (984.0m) | (32.0m) |

## Inventories | 70.0m | (461.0m) | 51.0m | 300.0m |

## Accounts Payable | 96.0m | 11.0m | 131.0m | 263.0m |

## Cash From Operating Activities | 6.5b | 6.9b | 8.4b | 8.0b |

## Purchases of PP&E | (1.5b) | (1.5b) | (1.3b) | (1.3b) |

## Cash From Investing Activities | (1.3b) | (1.4b) | (1.6b) | (5.4b) |

## Short-term Borrowings | (919.0m) | (3.2b) | (2.0b) | (4.2b) |

## Long-term Borrowings | (18.0m) | (23.0m) | (28.0m) | (214.0m) |

## Dividends Paid | (4.8b) | (3.9b) | (3.9b) | (4.3b) |

## Cash From Financing Activities | (6.4b) | (6.4b) | (6.4b) | (1.8b) |

## Net Change in Cash | (1.2b) | (905.0m) | 479.0m | 826.0m |

## Interest Paid | 732.0m | 781.0m | 766.0m | 895.0m |

## Income Taxes Paid | 1.6b | 1.3b | 1.3b | 1.5b |

GBP | FY, 2016 |
---|---|

## EV/EBIT | 41.4 x |

## EV/CFO | 16.6 x |

## Revenue/Employee | 280.9k |

## Debt/Equity | 3.8 x |

## Debt/Assets | 0.3 x |

## Financial Leverage | 11.9 x |

## P/E Ratio | 206.7 |

FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | |
---|---|---|---|---|

## Volume of Medicines Produced | 2 b | 1.9 b | 2.3 b | 2.3 b |

## Vaccines | 833 m | 798 m | 770 m | 701 m |

## Consumer Healthcare Products Produced | 5 b | 6.2 b | 3.8 b | 4.2 b |

## Vaccine Doses Delivered per Day | 2 m | 2 m | 2 m | 2 m |

## Healthcare Products in Development | 46 | 39 | ||

## Manufacturing Facilities | 87 | |||

## Markets | 150 | |||

## New Product Launches | 30 | |||

## Partners | 1.5 k | 2 k | ||

## Phase I Trials Products | 17 | 12 | ||

## Phase III Trials Products | 18 | 14 | ||

## Phase III Trials Products (Haemophilia) | 11 | 16 |

FY, 2019 | |
---|---|

## Water Used (Tankers) | 180 k cubic meters |

## Water Used (Municipal) | 8.8 m cubic meters |

## Water Used (Groundwater) | 3.38 m cubic meters |

## Water Used | 12.37 m cubic meters |

## Wastewater Discharged | 9.9 m cubic meters |

## Waste Generated | 117 k tonnes |

## Total Recordable Incident Rate | 0.22 |

## Total Energy Used | 4 m MWh |

## Number of Fatalities | 1 |

## Nonhazardous Waste (Landfilled) | 2.9 k tonnes |

## Lost Time Incident Rate | 0.14 |

## Lost Time Accidents | 289 |

## Hazardous Waste (Landfilled) | 100 tonnes |

## Greenhouse Gas Emissions (Scope 2) | 523 k metric tons of carbon dioxide equivalent |

## Greenhouse Gas Emissions (Scope 1) | 800 k metric tons of carbon dioxide equivalent |

## Greenhouse Gas Emissions (Scope 1 and Scope 2) | 1.32 m metric tons of carbon dioxide equivalent |

## Energy Used from Renewable Energy Sources (Purchased) | 51 k MWh |

## Energy Used from Renewable Energy Sources (On-Site Renewable Energy) | 25 k MWh |

## Energy Used (Steam) | 52 k MWh |

## Energy Used (Purchased Electricity) | 1.54 m MWh |

## Energy Used (Natural Gas) | 1.99 m MWh |

## Energy Used (Fuel and Other) | 92 k MWh |

## Energy Used (Electricity) | 1.55 m MWh |

## Energy Used (Coal) | 63 k MWh |

## Energy Used (Biomass) | 237 k MWh |

## Electricity Used from Renewable Energy Sources, percent | 5% |

## Diversion Rate | 79% |

GSK's employees are reported to be approximately 45% female and 55% male.

FY, 2019 | FY, 2018 | FY, 2017 | FY, 2016 | |
---|---|---|---|---|

Selling | 39.4% | 38.1% | 38% | 38.4% |

Manufacturing | 37.1% | 38.3% | 38.8% | 38.6% |

Research and Development | 12.1% | 12.4% | 11.7% | 11.6% |

Administration | 11.3% | 11.3% | 11.5% | 11.3% |

- Source: www.gsk.com, www.gsk.com, www.gsk.com

FY, 2019 | FY, 2018 | FY, 2017 | FY, 2016 | |
---|---|---|---|---|

Female | 45% | 44.9% | 44% | 43.5% |

Male | 55% | 55.1% | 56% | 56.5% |

- Source: www.gsk.com, www.gsk.com, www.gsk.com